Syros Pharmaceuticals, Inc. - stock earnings
SYRS Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 8, 2024 BeforeMarket | - / -0.8900000000 | - | - / 720000 | - |
SYRS Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -64.4 million USD | 386000 USD |
| 2023Q3 | -40.1 million USD | 3.8 million USD |
| 2023Q2 | -36.3 million USD | 2.8 million USD |
| 2023Q1 | -14.9 million USD | 3.0 million USD |
| 2022Q4 | 27.6 million USD | -5.5 million USD |
| 2022Q3 | -21.1 million USD | 3.9 million USD |
| 2022Q2 | -35.2 million USD | 6.3 million USD |
| 2022Q1 | -23.6 million USD | 5.5 million USD |
| 2021Q4 | -23.8 million USD | 7.8 million USD |
| 2021Q3 | -26.0 million USD | 5.7 million USD |
| 2021Q2 | -22.5 million USD | 5.2 million USD |
| 2021Q1 | -14.2 million USD | 4.8 million USD |
| 2020Q4 | -30.1 million USD | 5.7 million USD |
| 2020Q3 | -19.5 million USD | 3.8 million USD |
| 2020Q2 | -17.2 million USD | 3.2 million USD |
| 2020Q1 | -17.2 million USD | 2.4 million USD |
| 2019Q4 | -19.7 million USD | 508000 USD |
| 2019Q3 | -19.8 million USD | 558000 USD |
| 2019Q2 | -19.5 million USD | 462000 USD |
| 2019Q1 | -16.5 million USD | 454000 USD |
| 2018Q4 | -18.0 million USD | 893000 USD |
| 2018Q3 | -15.7 million USD | 412000 USD |
| 2018Q2 | -14.0 million USD | 375000 USD |
| 2018Q1 | -14.5 million USD | 370000 USD |
| 2017Q4 | -15.3 million USD | 1.1 million USD |
| 2017Q3 | -13.8 million USD | ? USD |
| 2017Q2 | -13.4 million USD | 1.1 million USD |
| 2017Q1 | -11.5 million USD | 1.1 million USD |
| 2016Q4 | -11.0 million USD | 317000 USD |
| 2016Q3 | -14.2 million USD | ? USD |
| 2016Q2 | -12.0 million USD | ? USD |
| 2016Q1 | -10.6 million USD | ? USD |
| 2015Q4 | -10.7 million USD | 317000 USD |
| 2015Q3 | -8.5 million USD | 317000 USD |
| 2015Q2 | -6.1 million USD | 317000 USD |
| 2015Q1 | -4.6 million USD | ? USD |
| 2014Q4 | -13.4 million USD | ? USD |
SYRS Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -164.6 million USD | 9.9 million USD |
| 2022 | -49.3 million USD | 14.9 million USD |
| 2021 | -90.5 million USD | 23.5 million USD |
| 2020 | -85.8 million USD | 15.1 million USD |
| 2019 | -75.4 million USD | 2.0 million USD |
| 2018 | -62.3 million USD | 2.1 million USD |
| 2017 | -54.0 million USD | 1.1 million USD |
| 2016 | -47.7 million USD | 317000 USD |
| 2015 | -29.8 million USD | 317000 USD |
| 2014 | -13.4 million USD | ? USD |
SYRS
Price: $5.15
52 week price:
Earnings Per Share: 0.85 USD
P/E Ratio: 8.42
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 234220
Ebitda: -13.6 millionMarket Capitalization: 137.1 million